Search Resources (English): Drug industry

Discusses diverse perspectives on the issue of women's health groups accepting money from the pharmaceutical industry.

Criticizes the Therapeutic Products Directorate (TPD), the arm of Health Canada in charge of testing and approving new drugs, particularly its dependence on funding from the pharmaceutical industry. Finds that these close ties with the pharmaceutical firms has led to the concealment of scientific or technical information about the safety and efficacy of new drugs.

Aims to provide the media, policy-makers, non-governmental organizations and other concerned groups with an introduction to the issues surrounding the international agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and public health.

Explores how the pharmaceutical industry encourages certain types of research that do not cure but require patients to remain on medication long term.

Looks at the impact of SSRI use among Canadian women. Reviews what is currently known about the benefits and harms caused by SSRIs, as well as both the definition and incidence of depression in women.

Examines whether Canadians can rely on daily newspapers to provide them with accuracte, credible information about new drugs. Demonstrates that newspaper articles more often emphasized the benefits of new drugs, paying less attention to possible harms, regardless of the length of the article and often failed to distinguish between real clinical benefits of a drug and merely changes in some measurement that is only a risk factor for disease. (See Details)

Debates that women, in particular, are vulnerable to the changes being wrought in the name of globalization. Discusses the negative impact that the pharmaceutical industry has had on women's health.

Provides a guide to obtaining reliable, independent and comparable information on medical products on the World Wide Web. Developed in consultation with drug regulatory authorities, drug information experts, consumer organizations and the pharmaceutical industry.

Discusses the origins of confidentiality in drug regulation, the scope of regulations, the development and consequence of excessive secrecy in drug regulation, the benefits of openness of drug information, and the need for transparency at the international level.